Orienting patients to greater opioid safety: Models of community pharmacy-based naloxone

Harm Reduction Journal

Volumn 12, Issue 1, 2015, Pages

  Green, Traci C ^a,b,c,f   Dauria, Emily F ^c   Bratberg, Jeffrey ^d   Davis, Corey S ^e   Walley, Alexander Y ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

^e Network for Public Health Law   (United States)

^f Boston University School of Medicine Boston Medical Center Clinical Addiction Research Education Unit ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; NALOXONE; NARCOTIC ANTAGONIST; PRESCRIPTION DRUG;

ARTICLE; CLINICAL COMPETENCE; CLINICAL PRACTICE; DRUG ABUSE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE DISTRIBUTION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; MEDICATION ERROR; PATIENT COUNSELING; PATIENT PARTICIPATION; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PHARMACY; PRESCRIPTION; PUBLIC HEALTH; RISK REDUCTION; UNITED STATES; COOPERATION; COUNSELING; DRUG USE; MASSACHUSETTS; NONBIOLOGICAL MODEL; OPIOID-RELATED DISORDERS; RHODE ISLAND;

COOPERATIVE BEHAVIOR; COUNSELING; DRUG OVERDOSE; DRUG USERS; HUMANS; MASSACHUSETTS; MODELS, ORGANIZATIONAL; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACEUTICAL SERVICES; PHARMACIES; PRESCRIPTION DRUGS; RHODE ISLAND; UNITED STATES;

EID: 84938598514     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-015-0058-x     Document Type: Article

References (76)

1. Medicines M. A brief history of pharmacy and pharmaceuticals London. UK: Pharmaceutical Press; 2005.
2. Gallup Inc. Honesty/Ethics in Professions. 2014. http://www.gallup.com/poll/1654/honesty-ethics-professions.aspx . Accessed October 30, 2014.
3. Ho JY. Mortality under age 50 accounts for much of the fact that US life expectancy lags that of other high-income countries. Health Aff (Millwood). 2013;32(3):459-67. doi:32/3/459 [pii] 10.1377/hlthaff.2012.0574.
4. Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011;81:1-8.
5. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS data brief, no 166. Hyattsville, MD: National Center for Health Statistics. 2014.
6. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses-a U.S. epidemic. Morb Mortal Wkly Rep. 2012;61(1):10-3.
7. EMCDDA. European drug report: trends and developments. Portugal: EMCDDA; 2015.
8. Mathers BM, Degenhardt L, Bucello C, Lemon L, Wiessig L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:102-23.
9. Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435-6.
10. Simini B. Balogna-Naloxone supplied to Italian heroin addicts. Lancet. 1998;352(9132):967.
11. Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80(2):288-90. doi: 10.1093/jurban/jtg031 .
12. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005;100(12):1823-31. doi:ADD1259 [pii] 10.1111/j.1360-0443.2005.01259.x [doi].
13. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89-96.
14. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303-11. doi: 10.1093/jurban/jti053 . jti053 [pii].
15. Wheeler E, Davidson PJ, Jones TS, Irwin KS. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. Morb Mortal Wkly Rep. 2012;61(6):101-5.
16. Wheeler E, Jones T, Gilbert M, Davidson P. Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014. Morb Mortal Wkly Rep. 2015;64(23):631-5.
17. Nacopoulos AG, Lewtas AJ, Ousterhout MM. Syringe exchange programs: impact on injection drug users and the role of the pharmacist from a U.S. perspective. Journal of American Pharmacists Association. 2010;50:147-57.
18. Martins S, van Mil JWF, da Costa F. The organizational framework of community pharmacies in Europe. Int J Clin Pharma. 2015:1-10. doi:10.1007/s11096-015-0140-1.
19. Doucette WR, McDonough RP. Beyond the 4Ps: using relationship marketing to build value and demand for pharmacy services. J Am Pharma Assoc (Washington,DC: 1996). 2002;42(2):183-93. quiz 93-4.
20. Matheson C, Bond C. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health. 2007;29:350-7.
21. Chaar BB, Hanrahan JR, Day C. Provision of opioid substitution therapy services in Australian pharmacies. Australian Medical Journal. 2011;4(4):210-6.
22. World Health Organization. Community management of opioid overdose. Geneva: World Health Organization; 2014.
23. Green TC, Grau LE, Blinnikova KN, Torban M, Krupitsky E, Ilyuk R, et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy. 2009;20(3):270-6. doi: 10.1016/j.drugpo.2008.07.002 . S0955-3959(08)00166-7 [pii].
24. Kan M, Gall JA, Latypov A, Gray R, Bakpayev M, Alisheva D, et al. Effective use of naloxone among people who inject drugs in Kyrgyzstan and Tajikistan using pharmacy- and community-based distribution approaches. Int J Drug Policy. 2014;25(6):1221-6. doi: 10.1016/j.drugpo.2014.01.005 . S0955-3959(14)00008-5 [pii].
25. Yo JY. Mortality under Age 50 accounts for much of the fact that US life expectancy lags that of other high-income countries. Health Aff. 2013;32(3):459-67.
26. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, et al. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013;53(3):273-81. doi:1686689 [pii] 10.1331/JAPhA.2013.12094.
27. Zaller ND, Yokell MA, Green TC, Gaggin J, Case P. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse. 2013;48(8):590-9. doi: 10.3109/10826084.2013.793355 .
28. Green TC, Bowman S, Yokell MA, McKenzie M, Roder-Hanna N, Zaller N, et al. Collaborative pharmacy practice agreements: a novel approach to expand naloxone access to reduce opioid overdose death. Washington, DC: American Public Health Association annual meeting; 2011.
29. Rose VJ, Lutnick A, Kral AH. Feasibility of providing interventions for injections drug users in pharmacy settings: a case study among San Francisco pharmacists. J Psychoactive Drugs. 2014;46(3):226-32.
30. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219-30.
31. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584-90. doi:199904060-00008 [pii].
32. Giglio R, Li G, DiMaggio C. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Injury Epidemiology. 2015;2:10.
33. Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297. doi:1471-2458-14-297 [pii]10.1186/1471-2458-14-297.
34. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009;99(5):788-91. doi:99/5/788 [pii] 10.2105/AJPH.2008.146647.
35. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
36. American Medical Association. AMA Adopts New Policies at Annual Meeting. 2012. https://www.ama-assn.org/ama/pub/news/news/2012-06-19-ama-adopts-new-policies.page . Accessed January 30 2015.
37. The White House. National drug control safety. In: Office of National Drug Control Policy. 2014.
38. Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41 Suppl 1:33-6. doi: 10.1111/jlme.12035 .
39. Davis C. Legal interventions to reduce overdose mortality. http://www.networkforphl.org . Accessed January 2, 2014.
40. Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health. 2014;104(8):e7-9. doi: 10.2105/AJPH.2014.302062 .
41. Davis CS, Southwell JK, Kiehaus VR, Walley AY, Dalley MW. Emergency medical services naloxone access: a national systematic legal review. Academy of Emergency Medicine. 2014;21(10):1173-7.
42. FDA Public Workshop. Role of Naloxone in Opioid Overdose Fatality Prevention Public Workshop, April 12, 2012 [online transcript]. U.S. Food and Drug Administration, Silver Spring, MD. 2012. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM304621.pdf . Accessed July 13, 2012.
43. Law AV, Gupta EK, Hata M, Hess KM, Klotz RS, Le QA, et al. Collaborative pharmacy practice: an update. Integrated Pharmacy Research and Practice. 2013;2:1-16.
44. American Pharmacists Association. Collaborative practice agreements vary among the states http://www.pharmacist.com/collaborative-practice-agreements-vary-among-states 2013. Accessed 9/29/13.
45. Centers for Disease Control and Prevention. WISQARS: Leading Causes of Death Reports, 1999-2007. National Center for Health Statistics (NCHS), National Vital Statistics System. 2007. http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html . Accessed Sept 11, 2011 2011.
46. SAMHSA. State estimates of substance Use from the 2007-2008 national surveys on drug Use and health. Rockville, MD: HHS Publication No. SMA 10-4472; 2010.
47. SAMHSA. State estimates of substance Use and mental disorders from the 2008-2009 national surveys on drug Use and health. HHS Publication No. (SMA) 11-4641: Rockville, MD; 2011.
48. SAMHSA. State Estimates of Nonmedical Use of Prescription Pain Relievers. http://archive.samhsa.gov/data/NSDUH/2k12State/NSDUHsae2012/Index.aspx . Accessed March 5, 2015.
49. Ogilvie L, Stanley C, Lewis L, Boyd M, Lozier M. Acetyl fentanyl overdose fatalities--Rhode Island, March-May 2013. MMWR Morb Mortal Wkly Rep. 2013;62(34):703-4. doi:mm6234a5 [pii].
50. Rhode Island Department of Health. Rules and Regulations Pertaining to Opioid Overdose Prevention. March 2014; R23-1 (3.10). http://sos.ri.gov/documents/archives/regdocs/released/pdf/DOH/7687.pdf . Accessed December 8, 2014.
51. Botticelli M. Office of National Drug Control Policy Update. Kansas City, MO: National Association of State Controlled Substances Authorities; 2013.
52. The Telegraph (editorial). The Screaming is Getting Louder. The NashuaTelegraph. May 5, 2015. http://www.nashuatelegraph.com/opinion/editorials/1062861-465/the-screaming-is-getting-louder.html . Accessed June 10, 2015.
53. Smith G. Deadly addiction: heroin deaths in Connecticut Up 86 percent from 2012 to 2014. Hartford Courant. 2015;26:2015.
54. Registry of Vital Records and Statistics. Data Brief: Fatal Opioid-related Overdoses among MA Residents. Boston: Massachusetts Department of Public Health; 2015.
55. Rhode Island Department of Health. Drug Overdoses. Providence, RI. 2015. http://www.health.ri.gov/data/drugoverdoses/ . Accessed June 15, 2015 2015.
56. Department of Health and Human Services. Dispensing of Naloxone by Standing Order Commonweath of Massachusetts, Boston. 2014. http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/dhpl/pharmacy/dispensing-of-naloxone-by-standing-order-.html . Accessed 1/25/15 2015.
57. Massachusetts General Law. Controlled Substances Act: Prescription, restrictions on issuance.94C § 19B. https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94C/Section19B . Accessed June 5, 2015.
58. Massachusetts General Law. Controlled Substances Act: Prescription, restrictions on issuance.94C § 19B(d). https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94C/Section19B . Accessed June 5, 2015.
59. Davis CS, Walley AY, Bridger CM. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics. 2015;43 Suppl 1:19-22. doi: 10.1111/jlme.12208 .
60. Hunter C. Take-home Naloxone: Legal Aspects. Edinburgh, Scotland. 2012. http://www.naloxone.org.uk/index.php/lawpolicy/law/uklaw1 . Accessed June 15, 2015.
61. Pharmacy Voice. Consultation response: MHRA MLX 383, Proposals for the amendments to the Human Medicines Regulations 2012 to allow wider access to Naloxone for use in emergencies. London, England2014. https://www.npa.co.uk/Documents/Docstore/Consultation-Responses/Joint_pharmacy_response_to_Consultation_on_measures_to_strengthen_the_medicines_supply_chain_and_reduce:the_risk_from_counterfeit_Medicines_FINAL.pdf . Accessed June 5, 2015.
62. Association of State and Territorial Health Officials. Operational Framework for Partnering with Pharmacies for Administration of 2009 H1N1 Vaccine2009. http://www.astho.org/Infectious-Disease/Operational-Framework-for-Partnering-with-Pharmacies-for-Administration-of-2009-H1N1-Vaccine/ . Accessed June 5, 2015.
63. Bailey AM, Wermeling DP. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. Ann Pharmacother. 2014;48(5):601-6. doi: 10.1177/1060028014523730 . 1060028014523730 [pii].
64. Zaller N, Jeronimo A, Bratberg J, Case P, Rich JD. Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence. RI J Urban Health. 2010;87(6):942-53. doi: 10.1007/s11524-010-9503-z .
65. Green TC, Bowman SE, Zaller ND, Ray M, Case P, Heimer R. Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders. Subst Use Misuse. 2013;48(7):558-67. doi: 10.3109/10826084.2013.787099 .
66. American Pharmacists Association. Controlled Substances and Other Medications with the Potential for Abuse and Use of Opioid Reversal Agents. 2014. www.pharmacist.com/policy/controlled-substances-and-other-medications-potential-abuse-and-use-opioid-reversal-agents-2 Accessed October 25, 2014.
67. National Association of Boards of Pharmacy. NABP Issues Policy Statement Supporting the Pharmacist's Role in Increasing Access to Opioid Overdose Reversal Drug. 2014. www.nabp.net/news/nabp-issues-policy-statement-supporting-the-pharmacist-s-role-in-increasing-access-to-opioid-overdose-reversal-drug . Accessed October 19, 2014.
68. McCauley JL, Back SE, Brady KT. Pilot of a brief, Web-based educational intervention targeting safe storage and disposal of prescription opioids. Addict Behav. 2013;38(6):2230-5. doi: 10.1016/j.addbeh.2013.01.019 .
69. Tanabe P, Paice JA, Stancati J, Fleming M. How do emergency department patients store and dispose of opioids after discharge? A pilot study. J Emerg Nurs. 2012;38(3):273-9. doi: 10.1016/j.jen.2011.09.023 . S0099-1767(11)00492-2 [pii].
70. Watson T, Hughes C. Pharmacists and harm reduction: a review of current practices and attitudes. Can Pharm J (Ott). 2012;145(3):124-7. doi: 10.3821/145.3.cpj124 . e2.
71. Brands J, Brands B, Marsh D. The expansion of methadone prescribing in Ontario, 1996-1998. Addiction Research and Theory. 2000;8(5):485-96.
72. Gerlach R. Drug-substitution treatment in Germany: a critical overview of its history, legislation and current practice. Journal of Drug Issues. 2002;0022:0426/02/02.
73. National Health Services Scotland. Forth Valley Community Pharmacy Naloxone Service. Edinburgh, Scotland. 2015. http://www.communitypharmacy.scot.nhs.uk/nhs_boards/NHS_Forth_Valley/redesign/LNS/naloxone.html . Accessed June 15, 2015.
74. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013;132(1-2):95-100. doi: 10.1016/j.drugalcdep.2013.01.007 . S0376-8716(13)00019-7 [pii].
75. Martins SS, Keyes KM, Storr CL, Zhu H, Grucza RA. Birth-cohort trends in lifetime and past-year prescription opioid-use disorder resulting from nonmedical use: results from two national surveys. J Stud Alcohol Drugs. 2010;71(4):480-7.
76. Duncan DF, Nicholson T, White JB, Bradley DB, Bonaguro J. The baby boomer effect: changing patterns of substance abuse among adults ages 55 and older. J Aging Soc Policy. 2010;22(3):237-48. doi:923475591 [pii] 10.1080/08959420.2010.485511 [doi].